文献速递冠心病

血浆RIPK3水平对急性心肌梗死PCI术后远期预后的影响

[Effect of plasma RIPK3 levels on long-term prognosis in patients with acute myocardial infarction undergoing percutaneous coronary intervention].
PubMed 文献 · Zhonghua Xin Xue Guan Bing Za Zhi · 2025-01-01

单中心前瞻性队列纳入103例PCI术后AMI患者,术后6小时测血浆RIPK3并随访约5.17年,44例(42.7%)发生MACE;RIPK3≥440.9 μg/L是MACE独立危险因素(HR=3.31,P=0.005),RIPK3联合传统危险因素预测效能优于单一指标。

要点

  • AMI患者PCI术后6小时血浆RIPK3≥440.9 μg/L与远期MACE风险升高独立相关。
  • RIPK3联合传统心血管危险因素的AUC为0.75,优于单一传统因素(0.68)或RIPK3(0.72)。
  • RIPK3高水平组PCI术后MACE风险显著高于低水平组(log-rank P=0.006)。

核心结论

  • 血浆RIPK3升高是AMI患者PCI术后发生MACE的独立危险因素。
  • RIPK3联合传统心血管危险因素可更有效预测AMI患者PCI术后MACE发生。
  • RIPK3≥440.9 μg/L的AMI患者PCI术后MACE风险高于低水平者。

研究设计与样本

  • 单中心前瞻性队列研究,纳入2017年9至11月北京协和医院接受PCI的AMI患者103例。
  • 术后6小时采集血浆测RIPK3,随访记录MACE(心血管死亡、心衰住院、再发AMI或卒中)。
  • 采用ROC曲线比较预测效能,多因素Cox回归分析RIPK3对MACE的影响,Kaplan-Meier及log-rank比较组间差异。

主要发现

  • 103例患者年龄63.0(56.0,69.0)岁,男性83例(80.6%);随访5.17(2.81,5.17)年,44例(42.7%)发生MACE。
  • 传统心血管危险因素AUC为0.68(95%CI:0.58~0.78),RIPK3的AUC为0.72(95%CI:0.62~0.82)。
  • 两者联合AUC为0.75(95%CI:0.65~0.85)。
  • 调整传统危险因素后,RIPK3≥440.9 μg/L是MACE独立危险因素(HR=3.31,95%CI:1.53~8.30,P=0.005)。
  • RIPK3高水平组MACE风险高于低水平组(log-rank P=0.006)。

关键数值与推荐

  • RIPK3最佳截断值为440.9 μg/L,用于分组及Cox分析。
  • MACE定义包括心血管死亡、因心力衰竭住院和血管事件(再发AMI或卒中)。

临床怎么用

  • PCI术后6小时血浆RIPK3≥440.9 μg/L可辅助识别AMI术后远期MACE高危患者。
  • RIPK3联合传统心血管危险因素可提升风险分层效能,供临床随访管理参考。

局限性

  • 单中心、样本量103例,结论外推需谨慎。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the impact of receptor-interacting protein kinase 3 (RIPK3) on major adverse cardiovascular events (MACE) in patients with acute myocardial infarction (AMI) after percutaneous coronary intervention (PCI), as well as the predictive performance of RIPK3 combined with traditional cardiovascular risk factors. Methods: This study was a single-center prospective cohort study. It included patients with AMI who underwent PCI at Peking Union Medical College Hospital between September 2017 and November 2017. Baseline clinical data were collected, and plasma samples were obtained 6 hours after PCI to measure RIPK3 levels. Follow-up was conducted via outpatient visits or phone calls to record the occurrence of MACE, including cardiovascular death, hospitalization for heart failure, and vascular events (recurrent AMI or stroke). The predictive performance of RIPK3, traditional cardiovascular risk factors and their combination for MACE was compared using receiver operating characteristic (ROC) curves. Patients were divided into low- and high-RIPK3 level groups based on the optimal cutoff value of RIPK3. Multivariate Cox proportional hazards regression analysis was used to assess the impact of RIPK3 levels on MACE after PCI in AMI patients. Kaplan-Meier survival curves were plotted, and the log-rank test was used to compare MACE incidence between the low-and high-RIPK3 groups. Results: A total of 103 AMI patients who underwent PCI were included, aged 63.0 (56.0, 69.0) years, and 83 (80.6%) were male. The follow-up time was 5.17 (2.81, 5.17) years, during which 44 patients (42.7%) experienced MACE. The ROC curve analysis showed that the area under the curve (AUC) for traditional cardiovascular risk factors was 0.68 (95%CI: 0.58-0.78), while the AUC for plasma RIPK3 was 0.72 (95%CI: 0.62-0.82). The combined AUC for traditional risk factors and RIPK3 was 0.75 (95%CI: 0.65-0.85). Multivariate Cox proportional hazards regression analysis indicated that plasma RIPK3 level is greater than or equal to the optimal cutoff value of 440.9 μg/L (HR=3.31, 95%CI: 1.53-8.30, P=0.005) was an independent risk factor for MACE in AMI patients after PCI. Kaplan-Meier survival analysis demonstrated that the high-RIPK3 group had a significantly higher risk of MACE after PCI compared to the low-RIPK3 group (log-rank P=0.006). Conclusions: Elevated plasma RIPK3 level is an independent risk factor for MACE in AMI patients after PCI. Plasma RIPK3 combined with traditional cardiovascular risk factors can more effectively predict the occurrence of MACE in AMI patients after PCI. AMI patients with RIPK3≥440.9 μg/L have a higher risk of MACE after PCI. 目的: 探讨急性心肌梗死患者(AMI)经皮冠状动脉介入治疗(PCI)术后受体相互作用蛋白激酶3(RIPK3)对主要不良心血管事件(MACE)的影响,以及RIPK3联合传统心血管危险因素的预测效能。 方法: 本研究为单中心前瞻性队列研究。纳入2017年9至11月在北京协和医院接受PCI治疗的AMI患者。收集患者的基本临床资料,在术后6 h采集血浆样本,测定RIPK3水平。出院后通过门诊或电话进行随访,记录患者MACE发生情况,包括心血管死亡、因心力衰竭住院和血管事件(再发AMI或卒中)。通过受试者工作特征曲线比较RIPK3、传统心血管因素及二者联合对MACE的预测效能,并根据RIPK3最佳截断值将患者分为RIPK3低水平组和高水平组。采用多因素Cox比例风险回归模型分析RIPK3水平对AMI患者PCI术后MACE的影响。绘制Kaplan-Meier生存曲线,采用log-rank法比较RIPK3低水平组和高水平组的MACE发生率。 结果: 纳入103例接受PCI的AMI患者,年龄为63.0(56.0,69.0)岁,男性83例(80.6%)。随访时间为5.17(2.81,5.17)年,共44例(42.7%)发生MACE。受试者工作特征曲线显示传统心血管危险因素的曲线下面积(AUC)为0.68(95%CI:0.58~0.78),PCI术后6 h血浆RIPK3的AUC为0.72(95%CI:0.62~0.82)。上述两者联合的AUC为0.75(95%CI:0.65~0.85)。多因素Cox比例风险回归模型分析显示,在调整了传统心血管危险因素后,RIPK3≥最佳截断值440.9 μg/L(HR=3.31,95%CI:1.53~8.30,P=0.005)是AMI患者PCI术后发生MACE的独立危险因素。Kaplan-Meier生存分析显示RIPK3高水平组的AMI患者PCI术后发生MACE的风险高于RIPK3低水平组(log-rank P=0.006)。 结论: RIPK3升高是AMI患者PCI术后发生MACE的独立危险因素。RIPK3水平联合传统心血管危险因素可以更有效地预测AMI患者PCI术后MACE的发生。RIPK3≥440.9 μg/L的AMI患者PCI术后发生MACE的风险高于RIPK3低水平者。.

来源:Zhonghua Xin Xue Guan Bing Za Zhi,查看原文。版权归原作者所有。

引用

  1. Wang, Lu, Zhang, et al. [Effect of plasma RIPK3 levels on long-term prognosis in patients with acute myocardial infarction undergoing percutaneous coronary intervention]. Zhonghua Xin Xue Guan Bing Za Zhi. 2025. PMID: 40091246. doi:10.3760/cma.j.cn112148-20241117-00707

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。